News
BCTXW
0.4029
+7.55%
0.0283
BRIACELL THERAPEUTICS ANNOUNCES CLOSING OF $5.5 MILLION PUBLIC OFFERING
Reuters · 5h ago
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer
Barchart · 20h ago
BRIACELL THERAPEUTICS CORP - PRICES PUBLIC OFFERING OF 7.4 MLN SHARES AND WARRANTS AT $0.75 EACH
Reuters · 1d ago
BRIACELL THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING
Reuters · 2d ago
BriaCell Therapeutics Announces Proposed Public Offering
Barchart · 2d ago
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®
Barchart · 2d ago
Briacell Therapeutics Corp <BCT.TO> expected to post a loss of 8 cents a share - Earnings Preview
Reuters · 3d ago
Weekly Report: what happened at BCTXW last week (1202-1206)?
Weekly Report · 4d ago
BRIACELL RECEIVES GREEN-LIGHT FROM DATA SAFETY MONITORING BOARD FOR ITS PHASE 3 STUDY IN METASTATIC BREAST CANCER
Reuters · 12/02 12:50
Weekly Report: what happened at BCTXW last week (1125-1129)?
Weekly Report · 12/02 12:31
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer
Barchart · 11/26 06:50
BRIACELL PROVIDES UPDATE TO ITS BOARD OF DIRECTORS
Reuters · 11/25 12:50
Weekly Report: what happened at BCTXW last week (1118-1122)?
Weekly Report · 11/25 12:19
BRIACELL ANNOUNCES FIRST PATIENT DOSED WITH BRIA-OTS™ IN METASTATIC BREAST CANCER STUDY
Reuters · 11/21 12:50
Weekly Report: what happened at BCTXW last week (1111-1115)?
Weekly Report · 11/18 12:15
Weekly Report: what happened at BCTXW last week (1104-1108)?
Weekly Report · 11/11 12:35
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
Barchart · 11/08 06:50
Weekly Report: what happened at BCTXW last week (1028-1101)?
Weekly Report · 11/04 12:30
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13
Barchart · 11/04 06:50
Briacell Therapeutics Corp reports results for the quarter ended in July 31 - Earnings Summary
Reuters · 10/29 02:26
More
Webull provides a variety of real-time BCTXW stock news. You can receive the latest news about Briacell Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About BCTXW
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.